Notably, all tumor relapse samples after ADT therapy exhibited very low TXNIP levels, indicating that low levels of TXNIP are needed for tumor recurrence; however, TXNIP levels pre-therapy did not forecast therapy response, although a trend was observed. The gene discussed is TXNIP; the disease is neoplasm.